Objective To identify risk factors associated with severe anaphylaxis in children STUDY DESIGN We carried out a multicenter prospective observational study including children less than 18 years old diagnosed with anaphylaxis in 7 Spanish pediatric emergency departments (ED) between May 2016 and April 2018. Children were considered to have severe anaphylaxis if they met one or more of the following criteria requirement for two or more doses of epinephrine, clinically important biphasic reaction, endotracheal intubation, intensive care unit admission, and/or death. Results We included 453 episodes of anaphylaxis. Of these, 61 were classified as severe anaphylaxis [13.5%, 95% CI (10.6-16.9)] 53 (11.7%) required more than one dose of epinephrine, and there were 14 (3.1%) cases of clinically important biphasic reactions, 2 (0.4%) intubations in the ED, and 6 (1.3%) admissions to the intensive care unit. No patients died. In the multivariable regression, we identified five independent risk factors for severe anaphylaxis history of asthma [p=0.002; OR 2.705, 95% CI (1.431-5.113)], onset of the symptoms less than 5 minutes after the allergen exposure [p=0.002; OR 2.619, 95% CI (1.410-4.866)], non-well appearance [P = .005; OR 2.973, 95% CI (1.380-6.405)], tachycardia [p=0.014; OR 2.339, 95% CI (1.191-4.959)] and hypotension [p=0.036; OR 3.725, 95% CI (1.087-12.762)] CONCLUSION Childhood anaphylaxis is usually well controlled in the ED. Children with a history of asthma, rapid onset of the symptoms, who are non-well appearing, or have tachycardia or hypotension upon arrival to the ED are more likely to have severe episodes.Objectives To compare patient reported outcomes in Blacks/African Americans with Whites participating in IBD Partners Kids & Teens, in order to identify possible racial health care disparities in pediatric inflammatory bowel disease (IBD) as future targets for improvement. Study design Cross-sectional analysis comparing patient reported outcomes in Black/African American with White patients, age 9-18 years, with IBD participating in the IBD Partners Kids & Teens cohort from 8/2013 to 4/2018. Secondary outcomes included number of IBD-related hospitalizations and surgeries, current medication use, and disease activity. Results We included 401 patients with Crohn's disease [White=378 (94%); Black/African American=23 (6%)]. For children with Crohn's disease, Black/African American patients compared with White patients reported less anxiety (40.7 versus 47.5, P=0.001) and fatigue (44.3 versus 48.4, P = .047) despite more frequently reported treatment with biologics (91% versus 61%, P=0.006) and antibiotics (17% versus 5%, P=0.03) and history of hospitalizations (81% versus 52%, P=0.02). Conclusions Black/African American children with Crohn's disease were less likely to report anxiety or fatigue than Whites, despite an apparent more severe disease course reflected by greater reported frequency of treatment with biologics and antibiotics and history of hospitalizations.Commensal microbes modulate the immune system in the colon via short-chain fatty acids (SCFA) which induce regulatory T cells (Treg). Accordingly, the SCFA sodium butyrate (SB) suppressed allergic contact dermatitis in mice via activation of Treg. There is evidence that Treg exert the capacity to control inflammation in psoriasis. Thus, we were interested to study the effect of SB in psoriasis, utilizing the imiquimod (IMQ)-induced psoriasis-like skin inflammation model. Topical application of IMQ induced thickening of the skin, scales and inflammation. This was associated with an upregulation of interleukin (IL)-17, downregulation of IL-10 and Foxp3. Topically applied SB reduced IMQ-induced inflammation and downregulated IL-17- and induced IL-10- and Foxp3-transcripts. The mitigating effect of SB was due to Treg, since it was lost upon depletion of Treg in DEREG mice. Treg isolated from blood of psoriatics were reduced in their suppressive activity which was normalized by SB. The fewer Treg numbers in biopsies of psoriatic lesions as well as enhanced IL-17-, IL-6- and reduced IL-10- and Foxp3-expression levels were restored by SB. These data indicate that psoriasis is associated with an impairment of Treg and an altered cytokine milieu. SCFA appear to restore these alterations thereby harboring therapeutic potential for psoriasis.Invasive studies show that the glomerular sieving coefficients for 5-30 kDa plasma proteins in the human kidney may be selectively reduced compared to those for small molecules less then 0.9 kDa, commonly used to measure glomerular filtration rate (GFR). Identification of this pathophysiological state, called shrunken pore syndrome (SPS), can easily and non-invasively be done by comparing estimations of GFR using cystatin C (13.3 kDa) and creatinine (0.113 kDa). SPS is present if the estimate of GFR using cystatin C is lower than 60 or 70% of the estimate using creatinine in the absence of non-renal influences on cystatin C or creatinine. All studies of SPS show that the 3- or 5-year mortality is strongly increased and high hazard ratios for mortality associated with SPS have been observed for many different patient cohorts, including cohorts with normal measured GFR, no albuminuria and no diagnosis. The prevalence of SPS in the cohorts so far investigated is between 0.2 and 36%. Proteome studies of SPS demonstrate that the high mortality associated with the syndrome might be caused by the accumulation of 10-30 kDa signalling proteins promoting development of atherosclerosis and thus suggesting use of monoclonal antibodies to reduce the levels of the most detrimental signalling proteins as a treatment option. The KDIGO recommendations for classification of chronic kidney disease (CKD) comprise determination, or estimation, of GFR and analysis of albuminuria and therefore cannot identify a large fraction of the patients with SPS. https://www.selleckchem.com/products/terephthalic-acid.html The high prevalence and mortality of SPS and the possible treatment options strongly suggest that the KDIGO recommendations should be expanded to include determination of cystatin C to be able to identify all patients with SPS.